Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: The HERNATA study

Journal of Clinical Oncology

Volumn 29, Issue 3, 2011, Pages 264-271

  Andersson, Michael ^a   Lidbrink, Elisabeth ^a   Bjerre, Karsten ^a   Wist, Erik ^a   Enevoldsen, Kristin ^a   Jensen, Anders B ^a   Karlsson, Per ^a   Tange, Ulla B ^a   Sørensen, Peter G ^a   Møller, Susanne ^a   Bergh, Jonas ^a   Langkjer, Sven T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NAVELBINE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; DIARRHEA; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INFECTION; LEUKOPENIA; LOADING DRUG DOSE; LUNG INFECTION; MAJOR CLINICAL STUDY; MOTOR NEUROPATHY; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SEPTICEMIA; SIDE EFFECT; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; TAXOIDS; VINBLASTINE;

EID: 79951974161     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.8213     Document Type: Article

References (20)

1. Hortobagyi GN, de la Garza SJ, Pritchard K, et al: The global breast cancer burden: Variations in epidemiology and survival. Clin Breast Cancer 6:391-401, 2005 (Pubitemid 43078894)
2. Albain KS, de la Garza SJ, Pienkowski T, et al: Reducing the global breast cancer burden: The importance of patterns of care research. Clin Breast Cancer 6:412-420, 2005 (Pubitemid 43078896)
3. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987 (Pubitemid 17231334)
4. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
5. Marty M, Cognetti F, Maraninchi D, et al: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 23:4265-4274, 2005 (Pubitemid 46207001)
6. Dawood S, Broglio K, Buzdar AU, et al: Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review. J Clin Oncol 28:92-98, 2010
7. Baker J, Ajani J, Scotte F, et al: Docetaxel-related side effects and their management. Eur J Oncol Nurs 13:49-59, 2009
8. Pegram MD, Konecny GE, O'Callaghan C, et al: Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96:739-749, 2004 (Pubitemid 38771819)
9. Nielsen DL, Andersson M, Kamby C: HER2-targeted therapy in breast cancer: Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat Rev 35:121-136, 2009
10. Burstein HJ, Harris LN, Marcom PK, et al: Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21:2889-2895, 2003 (Pubitemid 46621838)
11. Extra JM, Cognetti FC, Chan S, et al: First-line trastuzumab plus docetaxel versus docetaxel alone in women with HER2-positive metastatic breast cancer (MBC): Results from a randomised phase II trial (M77001). Breast Cancer Res Treat 82, 2003 (suppl 1, abstr 217)
12. Schoenfeld D: Residuals for the proportional hazards regression model. Biometrika 69:239-242, 1982
13. Wardley AM, Pivot X, Morales-Vasquez F, et al: Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J Clin Oncol 28:976-983, 2010
14. Pegram M, Forbes J, Pienkowski T, et al: BCIRG007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). J Clin Oncol 25:34s, 2007 (suppl; abstr LBA1008)
15. Burstein HJ, Keshaviah A, Baron AD, et al: Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study. Cancer 110:965-972, 2007 (Pubitemid 47312860)
16. De Laurentiis M, Cancello G, D'Agostino D, et al: Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-analysis of randomized trials. J Clin Oncol 26:44-53, 2008
17. Wang L, Jiang Z, Sui M, et al: The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: A case control study. BMC Cancer 9:226, 2009
18. Harris LN, You F, Schnitt SJ, et al: Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 13:1198-1207, 2007 (Pubitemid 46424061)
19. Roché H, Fumoleau P, Spielmann M, et al: Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: The FNCLCC PACS 01 Trial. J Clin Oncol 24:5664-5671, 2006 (Pubitemid 46631307)
20. Robert N, Leyland-Jones B, Asmar L, et al: Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24:2786-2792, 2006 (Pubitemid 46630577)